Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15111 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Huang-Chih Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University Colle…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kaohsiung Medical University Hospital.
Abstract (Originalsprache)
Background
Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor ( EGFR )‐mutated non‐small cell lung cancer (NSCLC), there is limited real‐world evidence comparing their effectiveness according to patients’ clinical characteristics. This network meta‐analysis (NMA) compared survival outcomes among first‐line EGFR‐TKIs in different subgroups of East Asian patients with advanced NSCLC.
Methods
This NMA included real‐world observational studies reporting outcomes with TKIs in patients aged >65 years, with baseline brain metastasis, with different Eastern Cooperative Oncology Group (ECOG) statuses, or with different common EGFR mutation types.
Results
In patients with the EGFR L858R mutation, afatinib resulted in significantly longer progression‐free survival (PFS) than erlotinib (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.46–0.75) and gefitinib (HR: 0.41, 95% CI: 0.32–0.53). Similarly, in patients with the EGFR Del19 mutation, afatinib and erlotinib resulted in significantly longer PFS than gefitinib (HR: 0.48 with 95% CI: 0.33–0.71 and HR: 0.54 with 95% CI: 0.36–0.80, respectively). Moreover, afatinib resulted in significantly longer PFS than gefitinib in patients with brain metastasis (HR: 0.53, 95% CI: 0.33–0.87) or ECOG status 0–1 (HR: 0.37, 95% CI: 0.23–0.59).
Conclusion
This NMA suggests that afatinib results in similar PFS to erlotinib and superior PFS than gefitinib in patients with Del19 mutant NSCLC, aged ≥65 years, with ECOG scores of 0–1, and with baseline brain metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, and Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi, Taiwan.
ORCID-Profile: Chin-Chou Wang, Hung-Yi Chuang
Förderung
- Kaohsiung Medical University Hospital
Zitieren
APA
Chang, H. C., Wang, C. C., Tseng, C. C., Huang, K. T., Chen, Y. M., Chang, Y. P., Lai, C. H., Fang, W. F., Lin, M. C., & Chuang, H. Y. (2023). Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15111
Vancouver
Chang HC, Wang CC, Tseng CC, Huang KT, Chen YM, Chang YP, et al. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15111
BibTeX
@article{Chang2023,
author = {Chang, Huang-Chih and Wang, Chin-Chou and Tseng, Chia-Cheng and Huang, Kuo-Tung and Chen, Yu-Mu and Chang, Yu-Ping and Lai, Chien-Hao and Fang, Wen-Feng and Lin, Meng-Chih and Chuang, Hung-Yi},
title = {Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15111}
}
EUVIMED